Scott M Wasserman
Overview
Explore the profile of Scott M Wasserman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
8408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Honda S, Puri R, Anderson T, Kastelein J, Brennan D, Kassahun H, et al.
JACC Cardiovasc Imaging
. 2021 Dec;
15(4):709-711.
PMID: 34922870
No abstract available.
2.
Nelson A, Puri R, Brennan D, Anderson T, Cho L, Ballantyne C, et al.
Am J Prev Cardiol
. 2021 Aug;
6:100153.
PMID: 34374706
[This corrects the article DOI: 10.1016/j.ajpc.2020.100091.].
3.
Nelson A, Puri R, Brennan D, Anderson T, Cho L, Ballantyne C, et al.
Am J Prev Cardiol
. 2021 Jul;
3:100091.
PMID: 34327467
Objective: On-treatment levels of high sensitivity C-reactive protein (hsCRP) in statin-treated patients predict plaque progression and the prospective risk of atherosclerotic cardiovascular events. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors...
4.
Giugliano R, Pedersen T, Saver J, Sever P, Keech A, Bohula E, et al.
Stroke
. 2020 Apr;
51(5):1546-1554.
PMID: 32312223
Background and Purpose- The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5-1.2) mmol/L and significantly reduced major vascular events...
5.
Koren M, Sabatine M, Giugliano R, Langslet G, Wiviott S, Ruzza A, et al.
J Am Coll Cardiol
. 2019 Oct;
74(17):2132-2146.
PMID: 31648705
Background: Evolocumab and other anti-PCSK9 antibodies reduced adverse cardiovascular outcomes in clinical trials of high-risk patients over <3 years median treatment duration. Objectives: The OSLER-1 trial (Open Label Study of...
6.
Charytan D, Sabatine M, Pedersen T, Im K, Park J, Lira Pineda A, et al.
J Am Coll Cardiol
. 2019 Jun;
73(23):2961-2970.
PMID: 31196453
Background: Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. Objectives: The purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function....
7.
Chan D, Watts G, Coll B, Wasserman S, Marcovina S, Barrett P
J Am Heart Assoc
. 2019 Mar;
8(7):e011781.
PMID: 30897995
Background Elevated lipoprotein(a) (Lp(a)), a low-density lipoprotein-like particle bound to the polymorphic apolipoprotein(a) (apo(a)), may be causal for cardiovascular disease. However, the metabolism of Lp(a) in humans is poorly understood....
8.
Lee E, Gibbs J, Emery M, Block G, Wasserman S, Hamilton L, et al.
Clin Pharmacol Drug Dev
. 2019 Jan;
8(3):281-289.
PMID: 30676701
We evaluated the pharmacokinetics, pharmacodynamics, and safety of evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), in an open-label, parallel-design study in participants with...
9.
ODonoghue M, Fazio S, Giugliano R, Stroes E, Kanevsky E, Gouni-Berthold I, et al.
Circulation
. 2018 Dec;
139(12):1483-1492.
PMID: 30586750
Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a)...
10.
Stiekema L, Stroes E, Verweij S, Kassahun H, Chen L, Wasserman S, et al.
Eur Heart J
. 2018 Dec;
40(33):2775-2781.
PMID: 30561610
Aims: Subjects with lipoprotein(a) [Lp(a)] elevation have increased arterial wall inflammation and cardiovascular risk. In patients at increased cardiovascular risk, arterial wall inflammation is reduced following lipid-lowering therapy by statin...